{"id":253052,"date":"2026-09-17T14:03:35","date_gmt":"2026-09-17T08:33:35","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=253052"},"modified":"2026-09-17T14:03:35","modified_gmt":"2026-09-17T08:33:35","slug":"zydus-lifesciences-stock-signals-investors-are-watching","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-stock-signals-investors-are-watching\/","title":{"rendered":"Zydus Lifesciences: 7 Stock Signals Investors Are Watching Right Now"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Zydus Lifesciences CMP Rs 1,112.4. 52W range Rs 836-1,205. Mcap Rs 1.10 lakh crore. PE 24.0 vs sector 37.4.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Zydus Lifesciences stock signals right now span an earnings picture, a shareholding pattern where promoter holding has been essentially flat at 75%, one of the highest promoter stakes among large-cap pharma companies, across the quarters the company has disclosed, and a technical setup where the stock trades well off its 52-week low of Rs 836. Debt to equity stands at 0.46, and valuation sits at a P\/E of 24.0 against a sector average of 37.4. Corporate developments in the pharmaceuticals, generics, biosimilars and vaccines space add further context investors are tracking alongside these numbers. None of the seven signals here amounts to a buy or sell call on its own.<\/p>\n<\/p><\/div>\n<p>Zydus Lifesciences stock signals are unusually layered right now, with the company trading at Rs 1,112.4, 7.7% below its 52-week high of Rs 1,205 and 33.1% above its 52-week low of Rs 836. Zydus Lifesciences is a well tracked name in the pharmaceuticals, generics, biosimilars and vaccines space, and no single headline captures where the stock stands today.<\/p>\n<p>This article does not make a buy, hold or sell call on Zydus Lifesciences. It lays out seven signals investors commonly watch, each sourced from the company&#8217;s latest exchange disclosures and financial statements, so readers can form their own view of what is currently working for the stock and what still needs to be watched.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=zydus-lifesciences-stock-signals-investors-are-watching\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-stock-signals-investors-are-watching\/#Zydus_Lifesciences_Stock_at_a_Glance\" title=\"Zydus Lifesciences Stock at a Glance\">Zydus Lifesciences Stock at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-stock-signals-investors-are-watching\/#1_Earnings_Trend_at_Zydus_Lifesciences\" title=\"1. Earnings Trend at Zydus Lifesciences\">1. Earnings Trend at Zydus Lifesciences<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-stock-signals-investors-are-watching\/#2_FII_Holding_in_Zydus_Lifesciences\" title=\"2. FII Holding in Zydus Lifesciences\">2. FII Holding in Zydus Lifesciences<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-stock-signals-investors-are-watching\/#3_Promoter_Holding_in_Zydus_Lifesciences\" title=\"3. Promoter Holding in Zydus Lifesciences\">3. Promoter Holding in Zydus Lifesciences<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-stock-signals-investors-are-watching\/#4_Debt_Position_at_Zydus_Lifesciences\" title=\"4. Debt Position at Zydus Lifesciences\">4. Debt Position at Zydus Lifesciences<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-stock-signals-investors-are-watching\/#5_Valuation_of_Zydus_Lifesciences_Shares\" title=\"5. Valuation of Zydus Lifesciences Shares\">5. Valuation of Zydus Lifesciences Shares<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-stock-signals-investors-are-watching\/#6_Technical_Trend_on_the_Zydus_Lifesciences_Chart\" title=\"6. Technical Trend on the Zydus Lifesciences Chart\">6. Technical Trend on the Zydus Lifesciences Chart<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-stock-signals-investors-are-watching\/#7_Corporate_Developments_at_Zydus_Lifesciences\" title=\"7. Corporate Developments at Zydus Lifesciences\">7. Corporate Developments at Zydus Lifesciences<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-stock-signals-investors-are-watching\/#What_These_Zydus_Lifesciences_stock_signals_Mean_Together\" title=\"What These Zydus Lifesciences stock signals Mean Together\">What These Zydus Lifesciences stock signals Mean Together<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-stock-signals-investors-are-watching\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-stock-signals-investors-are-watching\/#FAQs_on_Zydus_Lifesciences_Stock_Signals\" title=\"FAQs on Zydus Lifesciences Stock Signals\">FAQs on Zydus Lifesciences Stock Signals<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-stock-signals-investors-are-watching\/#Why_is_Zydus_Lifesciences_share_price_where_it_is_right_now\" title=\"Why is Zydus Lifesciences share price where it is right now?\">Why is Zydus Lifesciences share price where it is right now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-stock-signals-investors-are-watching\/#What_is_Zydus_Lifesciencess_current_FII_holding\" title=\"What is Zydus Lifesciences&#8217;s current FII holding?\">What is Zydus Lifesciences&#8217;s current FII holding?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-stock-signals-investors-are-watching\/#Is_Zydus_Lifesciencess_debt_position_a_concern_right_now\" title=\"Is Zydus Lifesciences&#8217;s debt position a concern right now?\">Is Zydus Lifesciences&#8217;s debt position a concern right now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-stock-signals-investors-are-watching\/#What_is_the_promoter_holding_in_Zydus_Lifesciences\" title=\"What is the promoter holding in Zydus Lifesciences?\">What is the promoter holding in Zydus Lifesciences?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-stock-signals-investors-are-watching\/#Is_Zydus_Lifesciences_expensive_compared_to_its_sector\" title=\"Is Zydus Lifesciences expensive compared to its sector?\">Is Zydus Lifesciences expensive compared to its sector?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-stock-signals-investors-are-watching\/#What_recent_corporate_developments_are_relevant_to_Zydus_Lifesciences\" title=\"What recent corporate developments are relevant to Zydus Lifesciences?\">What recent corporate developments are relevant to Zydus Lifesciences?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-stock-signals-investors-are-watching\/#What_do_the_technical_charts_suggest_about_Zydus_Lifesciences_right_now\" title=\"What do the technical charts suggest about Zydus Lifesciences right now?\">What do the technical charts suggest about Zydus Lifesciences right now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-stock-signals-investors-are-watching\/#Should_investors_buy_Zydus_Lifesciences_shares_at_current_levels\" title=\"Should investors buy Zydus Lifesciences shares at current levels?\">Should investors buy Zydus Lifesciences shares at current levels?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Zydus_Lifesciences_Stock_at_a_Glance\"><\/span><strong>Zydus Lifesciences Stock at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Before going through each of the seven Zydus Lifesciences stock signals in detail, the snapshot below sets the starting point on price, valuation and balance sheet strength.<\/p>\n<table style=\"width:100%;border-collapse:collapse;\">\n<tr>\n<th style=\"text-align:left;border-bottom:1px solid #ddd;padding:6px;\">Metric<\/th>\n<th style=\"text-align:left;border-bottom:1px solid #ddd;padding:6px;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"padding:6px;\"><a href=\"https:\/\/univest.in\/stocks\/zyduslife\/zydus-lifesciences-ltd-share-price-today\">Zydus Lifesciences<\/a> CMP<\/td>\n<td style=\"padding:6px;\">Rs 1,112.4 (NSE, 17 Sep 2026)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:6px;\">52-Week High<\/td>\n<td style=\"padding:6px;\">Rs 1,205 (10 August 2026)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:6px;\">52-Week Low<\/td>\n<td style=\"padding:6px;\">Rs 836 (30 March 2026)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:6px;\">Market Capitalisation<\/td>\n<td style=\"padding:6px;\">Rs 1.10 lakh crore<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:6px;\">P\/E Ratio<\/td>\n<td style=\"padding:6px;\">24.0 (Sector P\/E 37.4)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:6px;\">P\/B Ratio<\/td>\n<td style=\"padding:6px;\">4.07<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:6px;\">Debt to Equity<\/td>\n<td style=\"padding:6px;\">0.46<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:6px;\">Return on Equity<\/td>\n<td style=\"padding:6px;\">18.59%<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"1_Earnings_Trend_at_Zydus_Lifesciences\"><\/span><strong>1. Earnings Trend at Zydus Lifesciences<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Zydus Lifesciences closed the latest full year with revenue of Rs 27,658 crore versus Rs 23,511 crore a year earlier, while net profit moved to Rs 5,026 crore from Rs 4,615 crore, a change of 8.9% on the year. The most recent quarter added Rs 8,123 crore in revenue, a change of 20.7% year on year, against Rs 952 crore in net profit versus Rs 1,487 crore a year earlier.<\/p>\n<p>operating margin has eased from 34.7% to 25.9% over the last five quarters, and net profit was down close to 36% year on year in the June 2026 quarter even though full year FY26 profit still grew close to 9%. This is the first of the seven Zydus Lifesciences stock signals worth tracking closely into the next results.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"2_FII_Holding_in_Zydus_Lifesciences\"><\/span><strong>2. FII Holding in Zydus Lifesciences<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>FII holding in Zydus Lifesciences has declined from 7.5% to 6.88% across the last reported quarters (Dec &#8217;24 7.5%, Sep &#8217;25 7.3%, Dec &#8217;25 7.1%, Jun &#8217;26 6.88%). Domestic institutions have moved from 10.7% to 11.27% over the same stretch.<\/p>\n<p>Reading FII and DII holding together alongside the price action gives a fuller picture than either figure alone, since foreign and domestic flows do not always move in the same direction around a stock&#8217;s price swings.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"3_Promoter_Holding_in_Zydus_Lifesciences\"><\/span><strong>3. Promoter Holding in Zydus Lifesciences<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Promoter holding in Zydus Lifesciences has been essentially flat at 75%, one of the highest promoter stakes among large-cap pharma companies, across the quarters the company has disclosed, based on the last reported quarters (Dec &#8217;24 75.0%, Sep &#8217;25 75.0%, Dec &#8217;25 75.0%, Jun &#8217;26 75.01%).<\/p>\n<p>A stable or rising promoter stake is typically read as a sign that controlling shareholders have not used any recent price weakness to pare their position, though it is only one data point among the seven here.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"4_Debt_Position_at_Zydus_Lifesciences\"><\/span><strong>4. Debt Position at Zydus Lifesciences<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Zydus Lifesciences&#8217;s debt to equity ratio stands at 0.46, versus 0.09 in FY25 a year earlier, one of the balance sheet metrics worth tracking alongside the earnings trend above. A lower or stable ratio generally gives more room to fund growth without leaning further on external borrowing, while a rising one is worth watching for its effect on finance costs.<\/p>\n<p>This debt signal should be read alongside the valuation and corporate development signals below rather than in isolation, since capital raising plans can shift the picture from one quarter to the next.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"5_Valuation_of_Zydus_Lifesciences_Shares\"><\/span><strong>5. Valuation of Zydus Lifesciences Shares<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At the current price, Zydus Lifesciences trades at a price to earnings ratio of 24.0, a discount of close to 35.8% versus the sector average of 37.4. The price to book ratio stands at 4.07.<\/p>\n<p>Whether that discount looks justified depends on the earnings trend from Signal 1 continuing, and it is one of the clearer places where the seven signals can pull in different directions at the same time.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"6_Technical_Trend_on_the_Zydus_Lifesciences_Chart\"><\/span><strong>6. Technical Trend on the Zydus Lifesciences Chart<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The stock closed around Rs 1,112.4, positioned between its 50-day moving average of about Rs 1,134 and its 200-day moving average of about Rs 999, a mixed technical picture. The 14-day RSI reads close to 30, in neutral territory. The MACD line sits below its signal line, a bearish momentum bias on the daily chart.<\/p>\n<p>Over the past year the stock is currently 7.7% below its 52-week high of Rs 1,205 and 33.1% above its 52-week low of Rs 836. A sustained move back above the 50-day average would be an early technical sign of stabilisation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"7_Corporate_Developments_at_Zydus_Lifesciences\"><\/span><strong>7. Corporate Developments at Zydus Lifesciences<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Zydus Lifesciences completed the merger of US-based Assertio Holdings during the year, with Assertio shareholders receiving 23.5 dollars per share in cash, and CRISIL reaffirmed the company&#8217;s AAA\/Stable rating on Rs 4,724 crore of facilities and debt instruments in September 2026. The company is also set to participate in the J.P. Morgan India Conference on 21 September 2026.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live fundamentals<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_These_Zydus_Lifesciences_stock_signals_Mean_Together\"><\/span><strong>What These Zydus Lifesciences stock signals Mean Together<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>None of these seven signals on its own settles the debate on Zydus Lifesciences. Reading them as a set, rather than picking out any single one, is the more balanced way to approach the stock right now. The earnings trend, shareholding pattern, balance sheet position, valuation, technical setup and corporate developments each add one piece of the picture, and they do not all point the same way at the same time.<\/p>\n<p>Investors weighing Zydus Lifesciences would do well to watch the next quarterly results for a read on where margins and profit are heading, alongside the next shareholding pattern update for any shift in FII or promoter positioning. Reading these Zydus Lifesciences stock signals together, rather than in isolation, remains the more balanced approach. As with any single stock, price movements can be volatile and past trends do not guarantee future performance.<\/p>\n<p style=\"margin-top:24px;\"><em>Also Read: <a href=\"https:\/\/univest.in\/blogs\/hdfc-bank-stock-signals-investors-are-watching\/\">HDFC Bank: 7 Stock Signals Investors Are Watching Right Now<\/a><\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Zydus Lifesciences currently sits at the intersection of several moving parts, from earnings and shareholding to valuation and chart trend, and that is exactly what the seven signals above are meant to surface. This article does not recommend buying, holding or selling Zydus Lifesciences shares, and readers should form their own view based on their own research and risk appetite.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Zydus Lifesciences live price and more such signal based stock research.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information and the company&#8217;s exchange filings. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Zydus_Lifesciences_Stock_Signals\"><\/span><strong>FAQs on Zydus Lifesciences Stock Signals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Zydus_Lifesciences_share_price_where_it_is_right_now\"><\/span><strong>Why is Zydus Lifesciences share price where it is right now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Zydus Lifesciences shares are trading 7.7% below their 52-week high of Rs 1,205 and 33.1% above their 52-week low of Rs 836, shaped by the earnings trend, shareholding shifts and technical setup covered in this article, rather than any single factor.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Zydus_Lifesciencess_current_FII_holding\"><\/span><strong>What is Zydus Lifesciences&#8217;s current FII holding?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> FII holding in Zydus Lifesciences stood at 6.88% as of the most recent quarter.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Zydus_Lifesciencess_debt_position_a_concern_right_now\"><\/span><strong>Is Zydus Lifesciences&#8217;s debt position a concern right now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The debt to equity ratio stands at 0.46, versus 0.09 in FY25 a year earlier.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_promoter_holding_in_Zydus_Lifesciences\"><\/span><strong>What is the promoter holding in Zydus Lifesciences?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Promoter holding in Zydus Lifesciences stood at 75.01% as of the most recent quarter.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Zydus_Lifesciences_expensive_compared_to_its_sector\"><\/span><strong>Is Zydus Lifesciences expensive compared to its sector?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Zydus Lifesciences trades at a price to earnings ratio of 24.0 against a sector average of 37.4.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_recent_corporate_developments_are_relevant_to_Zydus_Lifesciences\"><\/span><strong>What recent corporate developments are relevant to Zydus Lifesciences?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Zydus Lifesciences completed the merger of US-based Assertio Holdings during the year, with Assertio shareholders receiving 23.5 dollars per share in cash, and CRISIL reaffirmed the company&#8217;s AAA\/Stable rating on Rs 4,724 crore of facilities and debt instruments in September 2026. The company is also set to participate in the J.P. Morgan India Conference on 21 September 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_do_the_technical_charts_suggest_about_Zydus_Lifesciences_right_now\"><\/span><strong>What do the technical charts suggest about Zydus Lifesciences right now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The stock is trading positioned between its 50-day moving average of about Rs 1,134 and its 200-day moving average of about Rs 999, a mixed technical picture, with a 14-day RSI near 30 and its MACD line below its signal line, a bearish momentum bias.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Should_investors_buy_Zydus_Lifesciences_shares_at_current_levels\"><\/span><strong>Should investors buy Zydus Lifesciences shares at current levels?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This article does not offer a buy, hold or sell recommendation. It lays out seven Zydus Lifesciences stock signals, earnings, FII holding, promoter holding, debt, valuation, technicals and corporate developments, so investors can weigh each signal and form their own view based on their goals and risk appetite.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Why is Zydus Lifesciences share price where it is right now?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Zydus Lifesciences shares are trading 7.7% below their 52-week high of Rs 1,205 and 33.1% above their 52-week low of Rs 836, shaped by the earnings trend, shareholding shifts and technical setup covered in this article, rather than any single factor.\"}},{\"@type\":\"Question\",\"name\":\"What is Zydus Lifesciences's current FII holding?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"FII holding in Zydus Lifesciences stood at 6.88% as of the most recent quarter.\"}},{\"@type\":\"Question\",\"name\":\"Is Zydus Lifesciences's debt position a concern right now?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The debt to equity ratio stands at 0.46, versus 0.09 in FY25 a year earlier.\"}},{\"@type\":\"Question\",\"name\":\"What is the promoter holding in Zydus Lifesciences?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Promoter holding in Zydus Lifesciences stood at 75.01% as of the most recent quarter.\"}},{\"@type\":\"Question\",\"name\":\"Is Zydus Lifesciences expensive compared to its sector?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Zydus Lifesciences trades at a price to earnings ratio of 24.0 against a sector average of 37.4.\"}},{\"@type\":\"Question\",\"name\":\"What recent corporate developments are relevant to Zydus Lifesciences?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Zydus Lifesciences completed the merger of US-based Assertio Holdings during the year, with Assertio shareholders receiving 23.5 dollars per share in cash, and CRISIL reaffirmed the company's AAA\/Stable rating on Rs 4,724 crore of facilities and debt instruments in September 2026. The company is also set to participate in the J.P. Morgan India Conference on 21 September 2026.\"}},{\"@type\":\"Question\",\"name\":\"What do the technical charts suggest about Zydus Lifesciences right now?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The stock is trading positioned between its 50-day moving average of about Rs 1,134 and its 200-day moving average of about Rs 999, a mixed technical picture, with a 14-day RSI near 30 and its MACD line below its signal line, a bearish momentum bias.\"}},{\"@type\":\"Question\",\"name\":\"Should investors buy Zydus Lifesciences shares at current levels?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This article does not offer a buy, hold or sell recommendation. It lays out seven Zydus Lifesciences stock signals, earnings, FII holding, promoter holding, debt, valuation, technicals and corporate developments, so investors can weigh each signal and form their own view based on their goals and risk appetite.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zydus Lifesciences stock signals right now: earnings, FII holding, promoter stake, debt, valuation, technical trend and corporate developments, all in one place, with no buy or sell call.<\/p>\n","protected":false},"author":29,"featured_media":253051,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[1007,1019],"class_list":["post-253052","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-pharma-stocks","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["253051"],"rank_math_title":["Zydus Lifesciences Stock Signals to Watch This Week"],"rank_math_description":["Earnings, FII holding, promoter stake, debt, valuation, technicals and corporate developments now shaping Zydus Lifesciences stock signals for investors."],"rank_math_focus_keyword":["Zydus Lifesciences stock signals"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/zydus-lifesciences-stock-signals-investors-are-watching.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/253052","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=253052"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/253052\/revisions"}],"predecessor-version":[{"id":253053,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/253052\/revisions\/253053"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/253051"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=253052"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=253052"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=253052"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}